GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » EBITDA Margin %

BioNexus Gene Lab (BioNexus Gene Lab) EBITDA Margin % : -2.06% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioNexus Gene Lab's EBITDA for the three months ended in Mar. 2024 was $-0.05 Mil. BioNexus Gene Lab's Revenue for the three months ended in Mar. 2024 was $2.38 Mil. Therefore, BioNexus Gene Lab's EBITDA margin for the quarter that ended in Mar. 2024 was -2.06%.


BioNexus Gene Lab EBITDA Margin % Historical Data

The historical data trend for BioNexus Gene Lab's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab EBITDA Margin % Chart

BioNexus Gene Lab Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial -174.80 12.07 8.71 -1.70 -25.43

BioNexus Gene Lab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.09 -9.66 -97.85 12.63 -2.06

Competitive Comparison of BioNexus Gene Lab's EBITDA Margin %

For the Specialty Chemicals subindustry, BioNexus Gene Lab's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNexus Gene Lab's EBITDA Margin % Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's EBITDA Margin % falls into.



BioNexus Gene Lab EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BioNexus Gene Lab's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-2.485/9.771
=-25.43 %

BioNexus Gene Lab's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-0.049/2.382
=-2.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioNexus Gene Lab  (NAS:BGLC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


BioNexus Gene Lab EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNexus Gene Lab (BioNexus Gene Lab) Business Description

Traded in Other Exchanges
N/A
Address
No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Executives
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong director, officer: President 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong officer: Chief Financial Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong director, officer: Chief Operating Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh director, officer: Chief Executive Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200